NTRA logo

Natera (NTRA) Stock

Profile

Full Name:

Natera, Inc.

Sector:

Healthcare

Country:

United States

IPO:

01 July 2015

Indexes:

Not included

Description:

Natera, Inc. is a diagnostic company that provides services in the field of reproductive health and genetic disease diagnostics. The company was founded in 2004 and is located in San Carlos, California. The company's main product is Panorama, a non-invasive prenatal test (NIPT) that detects fetal chromosomal abnormalities, including Down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, and triploidy. It also detects pathologies that often lead to intellectual disabilities, severe organ anomalies, and miscarriage. Panorama can also determine the sex of the fetus in a singleton pregnancy, as well as each fetus in a twin pregnancy. Panorama is also the only commercially available NIPT that can determine whether a set of twins is identical, monozygotic, dizygotic, or trizygotic.

Key Details

Price

$177.25

Annual Revenue

$1.08 B(+31.99% YoY)

Annual EPS

-$3.78(+32.14% YoY)

Annual ROE

-59.11%

Beta

1.62

Events Calendar

Earnings

Next earnings date:

Feb 28, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Feb 28, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

28 Jan '25 Goldman Sachs
Buy
23 Jan '25 Barclays
Overweight
17 Jan '25 Guggenheim
Buy
10 Jan '25 Bernstein
Outperform
03 Jan '25 Canaccord Genuity
Buy
13 Dec '24 JP Morgan
Overweight
18 Nov '24 Piper Sandler
Overweight
14 Nov '24 Morgan Stanley
Overweight
13 Nov '24 TD Cowen
Buy
13 Nov '24 JP Morgan
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
NTRA
businesswire.com25 January 2025

AUSTIN, Texas,--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has revealed new findings from the randomized, Phase III CALGB (Alliance) / SWOG 80702 study. These results will be shared today, January 25, 2025, during a late-breaking oral presentation at the 2025 American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA. This unique study looked into whether patients who tested positive for Signatera gain any advantages.

Natera to Present New Data at the 2025 ASCO GI Symposium
Natera to Present New Data at the 2025 ASCO GI Symposium
Natera to Present New Data at the 2025 ASCO GI Symposium
NTRA
businesswire.com21 January 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has announced the release of the first set of abstracts from various studies that will be presented at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium (ASCO GI) scheduled for January 23-25, 2025, in San Francisco, CA. New findings from the BESPOKE CRC study will be shared in an oral presentation on January 25.

Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
Natera Announces Preliminary Fourth Quarter and Full-Year Results for 2024
NTRA
businesswire.com12 January 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has shared its early unaudited results for the fourth quarter and the entire year ending December 31, 2024. The company anticipates total revenues of around $472 million for the fourth quarter of 2024, which is a 52% rise from $311 million in the same quarter of 2023. For the full year 2024, total revenues are expected to be about $1.7 billion.

Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +
Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +
Undercovered Dozen: Natera, Lloyds Banking Group, Eaton, Primoris Services +
NTRA
seekingalpha.com03 January 2025

The 'Undercovered' Dozen series showcases 12 stocks that don't get much attention, providing various investment options and sparking conversations among investors. Ready Capital Corporation has introduced new senior notes with a 9% yield, but they may be risky because of recent dividend cuts and poor earnings-to-debt ratios. Alex Pitti believes AVITA Medical has great growth potential due to new product launches and expanding market opportunities, making it an attractive long-term investment.

Natera: Poised For A Great Future But I'd Wait For A Pullback
Natera: Poised For A Great Future But I'd Wait For A Pullback
Natera: Poised For A Great Future But I'd Wait For A Pullback
NTRA
seekingalpha.com31 December 2024

Natera, a top company in cfDNA testing, has experienced significant growth and is close to making a profit, but its current market value seems too high. The company faces strong competition from others like Guardant Health and Quest Diagnostics, along with legal challenges that could be risky. While Natera's revenue is mainly boosted by its oncology division, especially the Signatera test, future growth might slow down as it approaches its total addressable market.

Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy?
Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy?
Natera (NTRA) Just Flashed Golden Cross Signal: Do You Buy?
NTRA
zacks.com17 December 2024

Natera (NTRA) has reached a key support level, making it a potentially strong stock choice based on technical analysis. The stock has also broken through the resistance at the 20-day moving average, indicating a positive trend in the short term.

Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
NTRA
businesswire.com27 November 2024

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has announced that its Prospera Lung test has fulfilled the coverage criteria set by the Centers for Medicare & Medicaid Services' (CMS) Molecular Diagnostics Services (MolDX) Program for single lung transplant (SLT) recipients. This coverage is relevant for SLT patients undergoing monitoring. SLT patients account for about 20% of all lung transplants in the U.S.1, and their numbers are rising.

Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
NTRA
businesswire.com25 November 2024

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a worldwide leader in cell-free DNA and genetic testing, has announced that it will showcase new data on SignateraTM at the San Antonio Breast Cancer Symposium (SABCS) from December 10-13 in San Antonio, TX. Natera and its partners will present six abstracts in total. "We are excited to share this new information on Signatera at SABCS, highlighting our dedication to providing evidence of its clinical benefits for patients."

Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
Federal Court Jury Issues Unanimous Verdict that Natera Engaged in False Advertising and Unfair Competition in Deliberate Attempt to Damage Guardant Health's Colorectal Cancer Test, Guardant Reveal™
NTRA
prnewswire.com25 November 2024

Guardant Health has achieved one of the largest verdicts for false advertising in history, marking an important win for colorectal cancer patients who may benefit from their product, Guardant Reveal™. A jury in California's U.S. District Court ruled unanimously in favor of Guardant Health in their lawsuit against Natera, which was accused of misleading oncologists to hinder competition. This decision highlights the significance of accurate information in the healthcare industry.

Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
NTRA
businesswire.com21 November 2024

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a leading company in cell-free DNA and genetic testing, has reached an important achievement by publishing over 100 peer-reviewed articles on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera. Several validation studies for Signatera have appeared in prestigious journals such as Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology.

FAQ

  • What is the primary business of Natera?
  • What is the ticker symbol for Natera?
  • Does Natera pay dividends?
  • What sector is Natera in?
  • What industry is Natera in?
  • What country is Natera based in?
  • When did Natera go public?
  • Is Natera in the S&P 500?
  • Is Natera in the NASDAQ 100?
  • Is Natera in the Dow Jones?
  • When was Natera's last earnings report?
  • When does Natera report earnings?
  • Should I buy Natera stock now?

What is the primary business of Natera?

Natera, Inc. is a diagnostic company that provides services in the field of reproductive health and genetic disease diagnostics. The company was founded in 2004 and is located in San Carlos, California. The company's main product is Panorama, a non-invasive prenatal test (NIPT) that detects fetal chromosomal abnormalities, including Down syndrome, Edwards syndrome, Patau syndrome, Turner syndrome, and triploidy. It also detects pathologies that often lead to intellectual disabilities, severe organ anomalies, and miscarriage. Panorama can also determine the sex of the fetus in a singleton pregnancy, as well as each fetus in a twin pregnancy. Panorama is also the only commercially available NIPT that can determine whether a set of twins is identical, monozygotic, dizygotic, or trizygotic.

What is the ticker symbol for Natera?

The ticker symbol for Natera is NASDAQ:NTRA

Does Natera pay dividends?

No, Natera does not pay dividends

What sector is Natera in?

Natera is in the Healthcare sector

What industry is Natera in?

Natera is in the Diagnostics & Research industry

What country is Natera based in?

Natera is headquartered in United States

When did Natera go public?

Natera's initial public offering (IPO) was on 01 July 2015

Is Natera in the S&P 500?

No, Natera is not included in the S&P 500 index

Is Natera in the NASDAQ 100?

No, Natera is not included in the NASDAQ 100 index

Is Natera in the Dow Jones?

No, Natera is not included in the Dow Jones index

When was Natera's last earnings report?

Natera's most recent earnings report was on 12 November 2024

When does Natera report earnings?

The next expected earnings date for Natera is 28 February 2025

Should I buy Natera stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions